Latest News for: Wamd

Edit

Replay KOL Webcast: Christian Pruente on wAMD and KIN001 (Kinarus Therapeutics Holding AG)

Public Technologies 28 Jun 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 62197168) .
Edit

Live KOL Webcast: Christian Pruente on wAMD and KIN001 (Kinarus Therapeutics Holding AG)

Public Technologies 27 Jun 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 62180751) .
Edit

Saudi Arabia.. “Tadawul” share jumps more than 10 percent on its first trading day

The Eastern Herald 08 Dec 2021
Saudi Stock Exchange run by Tadawul (File Photo) ... “Tadawul” includes four subsidiaries, namely, the Saudi Tadawul (as a stock market), a clearing center for securities company (clearing), the Securities Depository Center Company (Edaa), and the new Wamd Company, which specializes in services and technology solutions based on innovation.
Edit

The launch of the “Tadawul” company operating the Saudi Stock Exchange

The Eastern Herald 21 Nov 2021
Saudi flag ... “Tadawul” includes four subsidiaries, namely, the Saudi Tadawul (as a stock exchange), a clearing center for securities company (clearing), the Securities Depository Center Company (Edaa), and the new Wamd Company, which specializes in innovation-based technical services and solutions. Related. ... © The Eastern Herald ... ....
Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED IN AN EU COUNTRY (LATVIA) (Shanghai Henlius Biotech Inc)

Public Technologies 20 Apr 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED IN AN EU COUNTRY (LATVIA) INTRODUCTION ... macular degeneration (wAMD) indications.
Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA (Shanghai Henlius Biotech Inc)

Public Technologies 29 Jan 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA INTRODUCTION.
Edit

Opthea to Host Key Opinion Leader Symposium on wAMD and DME 2 pages ?Kb

Public Technologies 28 Jul 2020
The text version of this document in not available ... Disclaimer ... (noodl. 54775274) .
Edit

Opthea confirms final patient enrolment in Ph2b wAMD trial

Public Technologies 25 Nov 2018
ASX and Media Release 26 November 2018. Opthea Confirms Final Patient Enrolment in. Phase 2b Wet AMD Clinical Trial ... Today's announcement follows the randomization of an additional 15 patients who were undergoing eligibility screening when the Company recently successfully achieved its target enrolment of 351 treatment naïve patients into the study.
Edit

Opthea Phase 2b wAMD trial fully recruited ahead of schedule

Public Technologies 13 Nov 2018
ASX and Media Release 14 November 2018. Opthea Completes Patient Recruitment Ahead of Schedule in. Phase 2b Wet AMD Clinical Trial ... The randomization of 351 treatment naïve patients with wet AMD at 113 clinical sites in the United States, Europe and Israel was initiated in late December 2017 and has been completed ahead of the projected timelines ... Tel.
Edit

Opthea to Host wAMD and DME Key Opinion Leader Forum

Public Technologies 24 Sep 2018
ASX and Media Release 24 September 2018. Opthea to Host Wet AMD and Diabetic Macular Edema. Key Opinion Leader Forum in New York City ... The event will be held from 12.00PM - 2.00PM EST on Tuesday, November 6th, 2018 at the Parker New York Hotel in New York City ... Dr Rishi Singh, MD (Cleveland Clinic, Cleveland, OH) ... 10019-3318 ... About OPT-302 ... Curr Diab Rep.
Edit

Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD

Pharmiweb 20 Sep 2018
Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD ADVM-022 is a uni... .
Edit

Opthea presents Ph1/2a wAMD data at Retina Society Meeting

Public Technologies 14 Sep 2018
ASX and Media Release 14 September 2018. Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the. Retina Society 2018 Annual Meeting ... The additional study data presented for the first time by John A ... Similar gains in vision were also seen at week 8 and were observed as early as 4 weeks following combination treatment with OPT-302 and Lucentis®.
Edit

Opthea Receives Positive Safety Review for Ph2b wAMD Trial

Public Technologies 05 Sep 2018
ASX and Media Release 5 September 2018. Opthea Receives Positive Interim Review from Independent Safety. Committee in Phase 2b Wet AMD Clinical Trial ... A DSMB is a committee of independent clinical research experts who review patient safety data in ongoing clinical trials ... The Company remains on-track to report primary data from the study in early 2020.
Edit

Opthea reaches mid-way in recruitment for Ph2b wAMD trial

Public Technologies 02 Jul 2018
ASX and Media Release 2 July 2018. Opthea's Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of. Patient Recruitment. Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020 ... The Company remains on-track to report primary data from the study in early 2020 ... NCT03345082 and ID#. NCT03397264, respectively) ... About OPT-302.

Most Viewed

Hambantota Port
Creative Commons / Deneth17 / https://creativecommons.org/licenses/by-sa/3.0/deed.en
×